Hereditary Cancer Syndromes > BRCA 1
CANCER
GENETIC CANCER RISK
Female Breast
High Risk
Ovarian
High Risk
Male Breast
Elevated Risk
Pancreatic
Elevated Risk
Prostate
Elevated Risk
CANCER TYPE
AGE RANGE
CANCER RISK
RISK FOR
Female Breast
To age 50
28%-51%
1.9%
To age 70
46%-87%
7.1%
Second primary within 5 years of first breast cancer diagnosis
8.9%-20%
2%
Ovarian
To age 50
8%-23%
0.2%
To age 70
39%-63%
0.7%
Ovarian cancer within 10 years of a breast cancer diagnosis
12.7%
<1.0%
Prostate
To age 70
Up to 16%
6.6%
Male Breast
To age 70
1.2%
<0.1%
Pancreatic
To age 80
Elevated Risk
1%
CANCER TYPE
GENETIC CANCER RISK
CANCER RISK
RISK FOR
Female Breast
Breast awareness - Women should be familiar with their breasts and promptly report changes to their healthcare provider. Periodic, consistent breast self-examination (BSE) may facilitate breast awareness.
18 years
N/A
Clinical breast examination
25 years
Every 6 to 12 months
Breast MRI with contrast and/or mammography with consideration of tomosynthesis
Age 25 for MRI, or if MRI is unavailable, mammography with consideration of tomosynthesis. Age 30 for both MRI and mammography. Individualize to a younger age if a relative has been diagnosed younger than age 30.
Annually
Consider investigational screening studies within clinical trials.
Individualized
NA
Consider risk-reducing mastectomy.
Individualized
NA
Consider options for breast cancer risk-reduction agents (i.e. tamoxifen).
Individualized
NA
Ovarian
Bilateral salpingo-oophorectomy, considering both the possible increased risk for serous uterine cancer and the possible advantages of hormone replacement therapy with estrogen only
35 to 40 years, upon completion of childbearing
NA
Consider transvaginal ultrasound and CA-125 measurement. Consider investigational screening studies within clinical trials.
30 to 35 years
Individualized
Consider options for ovarian cancer risk-reduction agents (i.e. oral contraceptives).
Individualized
I'm a paragraph.
Prostate
Consider prostate cancer screening.
40 years
Individualized
Since mutation carriers are at an increased risk for more aggressive prostate cancer this information may be included as part of the risk and benefit discussion about prostate cancer screening.
NA
NA
Since mutation carriers are at an increased risk for more aggressive prostate cancer this information may be considered when choosing management options for men with a diagnosis of prostate cancer.
NA
NA
Male Breast
Breast self-examination
35 years
Monthly
Clinical breast examination
35 years
Annually
Consider mammography in men with gynecomastia (enlarged breasts)
50 years, or 10 years earlier than the youngest male breast cancer diagnosis in the family
Annually
Pancreatic
For patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in screening for pancreatic cancer, preferably within research protocols.
Age 50, or 10 years younger than the earliest age of pancreatic cancer diagnosis in the family
Annually
Provide education about ways to reduce pancreatic cancer risk, such as not smoking and losing weight.
Individualized
Individualized
For Patients With A Cancer Diagnosis
For patients with a gene mutation and a diagnosis of cancer, targeted therapies may be available as a treatment option for certain tumor types (e.g., platinum chemotherapy, PARP-inhibitors)
NA
NA
